Professional
Added to YB: 2024-08-14
Pitch date: 2024-06-30
CRL [bullish]
Charles River Laboratories International, Inc.
+40.48%
current return
Author Info
No bio for this author
Company Info
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
Market Cap
$13.4B
Pitch Price
$207.47
Price Target
N/A
Dividend
N/A
EV/EBITDA
16.99
P/E
-57.37
EV/Sales
4.07
Sector
Life Sciences Tools and Services
Category
growth
Ariel Small Cap Value Concentrated Portfolio Holding: Charles River Laboratories International, Inc.
CRL: Solid Q earnings beat despite cautious R&D funding. RMS & manufacturing up, DSA weak but recovering. Full-year guidance reiterated. Long-term bullish on biopharma demand for research models/services. Investing in cell/gene therapy capabilities. Expect margin expansion. Shares down with peers on near-term funding concerns.
Read full article (1 min)